Parlodel

A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. .
[PubChem].

Medicinal name:
  • Parlodel SnapTabs 2.5 MG Oral Tablet
  • Parlodel 5 MG Oral Capsule
  • Bromocriptine 5 MG Oral Capsule [Parlodel]
  • Bromocriptine 2.5 MG Oral Tablet [Parlodel]

Parlodel - Pharmacology:

Parlodel acts by directly stimulating the dopamine receptors in the corpus striatum.

Parlodel mini report

Parlodel NDA
NDA - A product marketed under an approved New Drug Application
Parlodel CAPSULE, GELATIN COATED
CAPSULE, GELATIN COATED
Parlodel TABLET
TABLET
Parlodel HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Parlodel global name
bromocriptine mesylate
Start - Stop data
START DATA:
2014-Apr-28
Start - Stop data
STOP DATA
not occurred

Parlodel for patients

During clinical trials, dizziness (8%-16%), drowsiness (8%), faintness, fainting (8%), and syncope (less than 1%) have been reported early in the course of Parlodel therapy. In post-marketing reports, Parlodel has been associated with somnolence, and episodes of sudden sleep onset, particularly in patients with Parkinsonís disease. Sudden onset of sleep during daily activities, in some cases without awareness or warning signs, has been reported very rarely. All patients receiving Parlodel should be cautioned with regard to engaging in activities requiring rapid and precise responses, such as driving an automobile or operating machinery.

Patients receiving Parlodel for hyperprolactinemic states associated with macroadenoma or those who have had previous transsphenoidal surgery, should be told to report any persistent watery nasal discharge to their physician. Patients receiving Parlodel for treatment of a macroadenoma should be told that discontinuation of drug may be associated with rapid regrowth of the tumor and recurrence of their original symptoms.

Parlodel Interactions

The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate. Parlodel mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents. Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide. Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.

Parlodel Contraindications

Uncontrolled hypertension and sensitivity to any ergot alkaloids. In patients being treated for hyperprolactinemia bromocriptine mesylate should be withdrawn when pregnancy is diagnosed. In the event that bromocriptine mesylate is reinstituted to control a rapidly expanding macroadenoma and a patient experiences a hypertensive disorder of pregnancy, the benefit of continuing bromocriptine mesylate must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy. When bromocriptine mesylate is being used to treat acromegaly, prolactinoma, or Parkinsonís disease in patients who subsequently become pregnant, a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn. If it is continued, the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy (including eclampsia, preeclampsia, or pregnancy-induced hypertension) unless withdrawal of bromocriptine mesylate is considered to be medically contraindicated. The drug should not be used during the post-partum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated. If the drug is used in the post-partum period the patient should be observed with caution.

Manufacturers name:

  • Validus Pharmaceuticals LLC
  • Novartis Pharmaceuticals Corporation

Generic name, Overdose, Half Life Parlodel, Food Interactions, Chemical, etc..

Parlodel see also Saw Palmetto

Women's Health
Brand Names containing Bromocriptine